Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.11 USD
Change Today -0.0025 / -2.22%
Volume 23.7K
SNWV On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

sanuwave health inc (SNWV) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/22/14 - $0.44
52 Week Low
05/7/15 - $0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANUWAVE HEALTH INC (SNWV)

Related News

No related news articles were found.

sanuwave health inc (SNWV) Related Businessweek News

No Related Businessweek News Found

sanuwave health inc (SNWV) Details

SANUWAVE Health, Inc., a shockwave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shockwaves for regenerative medicine and other applications. The company’s shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its lead product is the demaPACE device, which is in a supplemental Phase III clinical study for treating diabetic foot ulcers. The company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. It also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. The company sells its devices and accessories in Europe, Canada, and Asia/Pacific. SANUWAVE Health, Inc. was founded in 2005 and is based in Alpharetta, Georgia.

8 Employees
Last Reported Date: 03/3/15
Founded in 2005

sanuwave health inc (SNWV) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $90.0K
Compensation as of Fiscal Year 2014.

sanuwave health inc (SNWV) Key Developments

SANUWAVE Health, Inc. Announces Executive Changes

SANUWAVE Health, Inc. announced that Barry Jenkins, Chief Financial Officer, has resigned from the company to accept a top management position at a medical services company. To ensure a smooth transition, Mr. Jenkins will remain with the company through July 31, 2015. Lisa Sundstrom, the company's Controller since October 2006, will assume the additional duties of interim Chief Financial Officer. Ms. Sundstrom has over 23 years of financial and accounting experience, including the last nine years with SANUWAVE.

SANUWAVE Health, Inc. Announces Results of Shock Wave Technology for Biofilm Removal

SANUWAVE Health, Inc. announced the results of two poster presentations and a laboratory demonstration at the Center for Biofilm Engineering's 2015 Biofilm Science and Technology Meeting held at Montana State University in Bozeman, Montana on July 13-16, 2015. SANUWAVE's patented shock wave technology was evaluated in-vitro for effects on difficult to remove biofilms created by both Gram-negative bacteria (Pseudomonas aeruginosa) and Gram-positive bacteria (Staphylococcus aureus). Biofilms were exposed to focused acoustic shock waves and the application was performed without any contact between the shock wave applicator and the biofilm. The shock wave application to the biofilms resulted in a greater than three (3) log reductions (99.9%) from the surfaces exposed to the shock waves in certain tests for both bacteria test species. These results indicate that SANUWAVE's technology can effectively remove biofilms from surfaces using only the mechanical stresses produced by the shock waves. These tests indicate that SANUWAVE's technology could potentially reduce or eliminate the need to use chemicals, enzymes, or antibiotics to destroy and remove biofilms.

SANUWAVE Health Provides an Update on dermaPACE Clinical Trial

SANUWAVE Health, Inc. announced the plan for completing the company's Phase III supplemental clinical trial that used the dermaPACE® for treating diabetic foot ulcers. In addition, the FDA noted the totality of the data from the clinical study, such as additional endpoints and a favorable risk/benefit profile, will play an important role in the FDA's review of the Company's Premarket Approval (PMA) submission.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNWV:US $0.11 USD -0.0025

SNWV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Derma Sciences Inc $7.15 USD +0.02
Smith & Nephew PLC 1,189 GBp +22.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SNWV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANUWAVE HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at